Does Cigna Cover Lisinopril?

What Cigna's Formulary Says About Lisinopril

Lisinopril sits on Tier 1 of the Cigna standard formulary for most commercial plans, which is the preferred-generic tier with the lowest patient cost-share. Cigna's publicly posted formulary documents, updated annually under ACA requirements, list lisinopril (2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg tablets) without restrictions for hypertension and heart failure indications. Compounded lisinopril preparations, liquid suspensions, or doses outside the commercially available range may trigger a Prior Authorization (PA) requirement because the plan treats them as non-standard formulations.

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure by blocking the conversion of angiotensin I to angiotensin II, reducing peripheral vascular resistance. The FDA first approved lisinopril for hypertension, and subsequent approvals extended to adjunctive heart failure therapy and acute myocardial infarction management [1]. The drug also carries an established evidence base in diabetic nephropathy, where it reduces proteinuria and slows the progression of chronic kidney disease (CKD) [2].

Because lisinopril is a generic drug with a cash-pay price near $8 per month at major pharmacy chains, Cigna's financial incentive to restrict access is low. The plan formulary classifies it alongside other preferred ACE inhibitors such as enalapril and benazepril. Patients who verify coverage by calling the member services number on the back of their Cigna ID card, or by using Cigna's online formulary tool at MyCigna.com, will generally find their specific plan's tier and copay confirmed within minutes [3].

The 2017 ACC/AHA hypertension guideline explicitly recommends ACE inhibitors as first-line therapy for hypertension in patients with diabetes, CKD, or heart failure with reduced ejection fraction (HFrEF) [4]. Cigna's medical coverage policies align with these guidelines, which is one reason lisinopril receives preferred-tier status rather than a restricted tier requiring step therapy.

Prior Authorization for Lisinopril on Cigna

Prior authorization is not required for commercially available oral lisinopril tablets on the majority of Cigna plans. A PA may apply in three specific situations: compounded lisinopril preparations, doses above 40 mg per day (which exceed FDA labeling), and certain Cigna Connect or state Medicaid-managed plans that use a narrower formulary [5].

When a PA is required, Cigna's standard criteria for lisinopril-class drugs include confirmation of the FDA-approved diagnosis (hypertension, HFrEF, post-MI, or diabetic nephropathy), the prescribing physician's specialty and DEA number, and documentation that the patient has no contraindications such as a history of ACE inhibitor-induced angioedema. Cigna uses its internal pharmacy and therapeutics (P&T) committee determinations, which typically mirror clinical guideline thresholds.

The ALLHAT trial (N=33,357, JAMA 2002) remains the largest randomized comparison of antihypertensive drug classes. It found that chlorthalidone, amlodipine, and lisinopril produced similar rates of fatal coronary heart disease and nonfatal myocardial infarction over a mean follow-up of 4.9 years [6]. Cigna's P&T committee cites evidence of this caliber when deciding which agents receive preferred status. Lisinopril's strong safety record in ALLHAT, combined with its generic price point, keeps it firmly in the preferred tier.

If a PA is required for your specific plan, your prescribing physician submits a PA request through Cigna's provider portal or by fax. Cigna is required by federal law to issue an urgent-care PA decision within 72 hours and a standard PA decision within 15 calendar days [7]. Physician offices that use electronic health record (EHR) integrations with Cigna's CoverMyMeds platform may receive decisions in under 24 hours for standard cases.

The HealthRX PA Readiness Checklist for lisinopril includes five items your physician's office should have ready before submitting: (1) confirmed diagnosis code (ICD-10: I10 for hypertension, I50.x for heart failure, N18.x for CKD), (2) current blood pressure readings or ejection fraction measurements from the chart, (3) any documentation of prior antihypertensive trials if the plan asks for them, (4) the specific lisinopril formulation and dose requested, and (5) a note addressing any alternative agents the plan might prefer so the reviewer can see they have been considered.

Step Therapy Requirements and Lisinopril

Cigna does not impose step therapy before dispensing lisinopril for hypertension on most commercial plans. Lisinopril itself is a first-line agent under every major U.S. hypertension guideline, including the 2017 ACC/AHA guideline [4] and the Eighth Joint National Committee (JNC 8) 2014 recommendations [8]. Requiring a patient to fail a cheaper drug before accessing lisinopril would be clinically backwards because lisinopril is among the cheapest antihypertensives available.

Step therapy requirements are more commonly seen when a patient requests a branded ACE inhibitor (for example, Zestril or Prinivil) instead of generic lisinopril. In those cases, Cigna's step-therapy protocol typically requires documentation that generic lisinopril was tried and produced a specific adverse effect or failed to achieve blood pressure control. The protocol usually requires one prior trial of the generic [9].

Patients with diabetic nephropathy or CKD warrant special attention. The American Diabetes Association's Standards of Care (2024 update) recommends ACE inhibitors or ARBs as preferred agents for CKD patients with albuminuria above 300 mg per gram of creatinine [10]. Cigna's coverage policies for renal indications follow this framework, meaning lisinopril carries a clinical rationale that makes step-therapy bypass arguments straightforward when the prescriber documents the CKD diagnosis and albuminuria level [11].

For heart failure with reduced ejection fraction, the 2022 AHA/ACC/HFSA Heart Failure Guideline gives ACE inhibitors a Class I recommendation as a cornerstone of neurohormonal blockade therapy, particularly when sacubitril/valsartan (Entresto) is not tolerated or accessible [12]. If Cigna's plan requires step therapy toward a branded heart failure agent, the lisinopril trial itself serves as the required step, so starting with lisinopril satisfies the criterion before a branded drug is considered.

How Much Does Lisinopril Cost with Cigna?

The typical Cigna commercial plan copay for Tier 1 generic lisinopril runs $0 to $15 per 30-day supply at in-network pharmacies. High-deductible health plans (HDHPs) will charge the actual negotiated cost until the deductible is met; after the deductible, the Tier 1 copay applies [13].

Without insurance, lisinopril costs approximately $8 per month at GoodRx prices at major chains such as CVS, Walgreens, and Walmart. The manufacturer reference list price is approximately $50 per month for branded versions, but branded lisinopril is rarely dispensed because the generic is therapeutically equivalent.

The Cigna Patient Assurance Program, where available, caps out-of-pocket costs for certain drugs at $25 per month for eligible members. Lisinopril at its generic price point is unlikely to benefit from manufacturer savings cards because the drug is already priced below what most copay assistance programs target. Manufacturer copay cards typically exclude generic drugs and are designed for branded agents, so a patient paying $8 cash or a $5 Cigna copay would receive no additional savings from a manufacturer card [14].

Pharmacy benefit manager (PBM) rebates also reduce Cigna's net drug cost for ACE inhibitors. GoodRx and SingleCare discount cards may reduce cash-pay costs further at pharmacies not participating in Cigna's network, and patients are allowed to use cash-pay pricing rather than insurance when cash-pay is lower.

How to Appeal a Cigna Denial of Lisinopril

A Cigna denial of lisinopril is uncommon for standard oral tablets but does occur for compounded formulations, doses above FDA labeling, or plans with narrow formularies. When a denial occurs, Cigna is required by ACA Section 2719 and ERISA to provide a written explanation of the denial and clear instructions for the appeal process [15].

The Cigna internal appeal process has two levels. Level 1 is a standard internal appeal reviewed by a clinician not involved in the original denial. Cigna must respond within 30 days for non-urgent pharmacy appeals or 72 hours for urgent appeals. Level 2 is a second internal appeal if Level 1 fails. After exhausting both internal levels, members may request an external review by an Independent Review Organization (IRO) certified by the state [16].

The strongest appeals for lisinopril denials rest on three clinical pillars: guideline support (citing ACC/AHA and JNC 8 first-line status), diagnosis documentation (ICD-10 codes with objective measurements such as blood pressure readings above 130/80 mmHg or an ejection fraction below 40%), and intolerance records for any alternative the plan proposed. The 2017 ACC/AHA hypertension guideline defines stage 1 hypertension as systolic blood pressure 130 to 139 mmHg or diastolic 80 to 89 mmHg [4], a threshold that supports medical necessity documentation in appeal letters.

Your physician should submit the appeal letter, relevant chart notes, current blood pressure logs, laboratory values (serum creatinine, potassium, urine albumin-to-creatinine ratio), and copies of the relevant guideline pages. A sample appeal phrase grounded in guideline language: "The 2017 ACC/AHA Hypertension Guideline (Whelton et al.) assigns a Class I, Level A recommendation to ACE inhibitor therapy for this patient's documented diagnosis of CKD with albuminuria, meeting Cigna's criteria for medical necessity under its own coverage policy" [4].

Cigna's external IRO review is conducted by an organization independent of Cigna and is legally binding on the plan. National studies show that external review overturn rates for pharmacy denials hover around 39 to 45%, meaning nearly half of patients who reach external review win their case [17]. Filing for external review costs nothing for the member.

Cigna Coverage of Lisinopril for Specific Conditions

Hypertension

Lisinopril is covered by Cigna for hypertension without PA for standard oral doses up to 40 mg per day. The ALLHAT trial confirmed non-inferiority of lisinopril to chlorthalidone for the primary outcome of combined fatal coronary heart disease and nonfatal MI in 33,357 high-risk hypertensive patients followed for a mean of 4.9 years [6]. Blood pressure goals per JNC 8 for patients without diabetes or CKD are <140/90 mmHg; for patients with diabetes or CKD, <130/80 mmHg per the 2017 ACC/AHA guideline [4] [8].

Heart Failure

For HFrEF with an ejection fraction below 40%, lisinopril is covered as an ACE inhibitor under Cigna's heart failure benefit. The SOLVD treatment trial (N=2,569) showed that enalapril, a closely related ACE inhibitor, reduced all-cause mortality by 16% and heart failure hospitalizations by 26% versus placebo over a mean of 41.4 months, a result that established class-level evidence for ACE inhibitors including lisinopril [18]. Cigna's heart failure medical policy requires documentation of an echocardiogram or cardiac imaging confirming reduced ejection fraction for PA requests related to higher doses or branded formulations.

Diabetic Nephropathy and CKD

Lisinopril reduces proteinuria in type 1 and type 2 diabetic nephropathy. The Collaborative Study Group trial showed captopril (another ACE inhibitor) reduced the risk of doubling of serum creatinine by 48% versus placebo in type 1 diabetic nephropathy (P<0.001) [19]. Cigna covers lisinopril for CKD with albuminuria following ADA 2024 Standards of Care recommendations, provided the prescriber documents urine albumin-to-creatinine ratio and estimated glomerular filtration rate (eGFR) in the chart [10].

Acute Myocardial Infarction

Lisinopril's FDA label includes an indication for hemodynamically stable acute MI within 24 hours of onset [1]. Cigna covers this indication under inpatient pharmacy benefits during hospitalization; outpatient continuation falls under the standard Tier 1 formulary benefit without PA.

What Cigna Does Not Cover: Lisinopril Exceptions

Cigna explicitly excludes or restricts coverage in three scenarios. First, compounded lisinopril oral suspensions require PA with documentation of a clinical reason the commercially available tablet cannot be used (for example, a pediatric patient who cannot swallow tablets). Second, lisinopril prescribed solely for weight loss is not a covered indication, as the FDA has not approved ACE inhibitors for obesity treatment and the clinical evidence does not support this use [20]. Third, doses exceeding 40 mg per day fall outside FDA labeling and require PA with specialist documentation.

Cigna's benefit exclusion language states that coverage applies only to "medically necessary services for treatment of illness or injury" as defined in each member's Evidence of Coverage document. Off-label prescribing of lisinopril for weight loss does not meet this standard.

Verifying Your Specific Cigna Plan Coverage

Cigna offers more than 30 distinct plan types, including Connect, Open Access Plus, LocalPlus, SureFit, Medicare Advantage, and various Medicaid-managed care products. Formulary tiers and PA requirements can vary across these plan types even when the member lives in the same zip code. Three reliable ways to confirm lisinopril coverage exist.

Call the pharmacy benefit number on the back of your Cigna ID card and ask specifically for the formulary tier, copay amount, quantity limit, and whether PA is required for your prescribed dose. Use the formulary search tool at MyCigna.com with your plan ID. Ask your pharmacy to run a test claim before you arrive to pick up the prescription; the pharmacy system will return the real-time copay and flag any PA requirement [21].

If you receive a Cigna Medicare Advantage plan, the Part D formulary is filed annually with the Centers for Medicare and Medicaid Services (CMS) and must cover all Part D drugs on the CMS protected drug class list. Lisinopril is a generic drug covered under Part D formularies, and Medicare Advantage plans must follow CMS coverage requirements, including the right to a Coverage Determination and the right to appeal through the Medicare Part D appeals process [22].